Kort Nieuws
-
8 mei 2022Andy Warhol Foundation v. Goldsmith: The Supreme Court Revisits Transformative Fair Uses
-
3 mei 2022Juridisch advies van Nederlandse bodem bij Amerikaanse overname Karl Lagerfeld
-
2 mei 2022Brands to the Metaverse and Beyond! Part 1…
-
2 mei 2022Vans Can Halt Sales Of Tyga's 'Wavy Baby' Shoes In TM Row
-
2 mei 2022Albright Won't Ship Patent Suit Over HPE Data Tech To Mass.
-
2 mei 2022Chinese Citizen Convicted Of Stealing GSK Trade Secrets
-
2 mei 2022Machine Learning Tech Remains A Challenge In Patent Claims
-
2 mei 2022Our Courts Must End Big Tech's Patent Plunder
-
2 mei 2022Michaels Can't Duck Decor Co.'s Frame Trademark Suit
-
1 mei 2022[Guest Post] WIPO’s African Group hits the ground running with a Work Program on Copyright Limitations and Exceptions
-
1 mei 2022The UK IPO publishes its Research Priorities for 2022-23
-
27 april 2022Non-domestication of TRIPS Agreement and the Paris Convention means no protection yet for well-known marks in Nigeria
-
27 april 2022Article 17 survives, but freedom of expression safeguards are key: C-401/19 – Poland v Parliament and Council
-
27 april 2022Va. Judge Won't Toss German Supplier's Laminate TM Suit
-
27 april 2022CJEU upholds Article 17, but not in the form (most) Member States imagined
-
25 april 2022BREAKING: Article 17 of the DSM Directive is VALID
-
25 april 2022Article 17 of the DSM Directive is valid: an early take on today’s Grand Chamber ruling
-
25 april 2022Software Co. Gets Partial Win In Copyright Fight With Feds
-
24 april 2022AI Music Outputs: Challenges to the Copyright Legal Framework – Part II
-
24 april 2022Opnieuw illegaal online aanbod stripbladen aangepakt
- KORT NIEUWS
-
31 maartBreed vervolg handhaving tegen illegaal vinyl
-
31 maartDean Lewis verliest rechtszaak tegen Nederlandse vrouw
-
30 maartAG Emiliou advises CJEU to rule that OCSSPs' authorization under Article 17 of the DSM Directive extends to acts of reproduction
-
30 maartMAN v Rolls-Royce – How not to advertise your mark
-
30 maartPatenting stem cell therapies in the US: The role and risks of product-by-process claims (Restem v Jadi cell)























































































